ClinicalTrials.gg
CompletedNCT03740165Updated Aug 19, 2026Results posted

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

A Phase 3 interventional study of Pembrolizumab and Placebo for pembrolizumab in Ovarian Cancer, Fallopian Tube Cancer and Peritoneal Neoplasms, sponsored by Merck Sharp & Dohme LLC. Completed at 227 sites in 22 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,367
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies testing pembrolizumab in Ovarian Neoplasms — 7 open to participants now, 13 under way, 2 of them phase 3. pembrolizumab · Ovarian Neoplasms.

Enrollment
Largest of 35
1,367 · median 38
Started
2018
with 6 others
Phase 3
2 of 35
none open now
Registered
21st of 35
by date
Lead sponsor
4 of 35
Merck Sharp & Dohme LLC

Among the 35 studies testing pembrolizumab in Ovarian Neoplasms, this one has the largest enrollment, is one of 7 that started in 2018, is one of 2 in phase 3, and was the 21st registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

7 of the 35 studies testing pembrolizumab in Ovarian Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies testing pembrolizumab in Ovarian Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of treatment with carboplatin/paclitaxel* PLUS pembrolizumab (MK-3475) and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian tube cancer, or primary peritoneal cancer.

The primary study hypotheses are that the combination of pembrolizumab plus carboplatin/paclitaxel* followed by continued pembrolizumab and maintenance olaparib is superior to carboplatin/paclitaxel alone with respect to Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in participants with programmed death-ligand 1 (PD-L1) positive tumors (Combined Positive Score [CPS]≥10) and in all participants, and that the combination of pembrolizumab plus carboplatin/paclitaxel followed by continued pembrolizumab is superior to carboplatin/paclitaxel alone with respect to PFS per RECIST 1.1 in participants with PD-L1 positive tumors (CPS≥10) and in all participants.

Read the detailed description

Following a lead-in period during which all participants receive a single 3-week cycle of carboplatin/paclitaxel*, participants will be randomly assigned in to one of three treatment arms, and will receive carboplatin/paclitaxel* for 5 cycles plus:

  • Pembrolizumab + Olaparib
  • Pembrolizumab + Placebo for Olaparib
  • Placebo for Pembrolizumab + Placebo for Olaparib

    • At Investigator's discretion and prior to participant randomization, one of the following carboplatin/paclitaxel regimens is to be selected:

      1. up to 5 cycles of carboplatin Area Under the Curve (AUC)5 or AUC6 AND paclitaxel 175 mg/m\^2 on Day 1 of each 3-week cycle
      2. up to 5 cycles of carboplatin AUC5 or AUC6 on Day 1 of each 3-week cycle AND paclitaxel 80 mg/m\^2 on Days 1, 8 and 15 of each 3-week cycle; or
      3. up to 5 cycles of carboplatin AUC2 or AUC2.7 AND paclitaxel 60 mg/m\^2 on Days 1, 8 and 15 of each 3-week cycle.

Docetaxel may be considered for participants who experience either a severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel only after consultation with the Sponsor. The recommended dose as determined by the Scottish Gynaecological Cancer Trials Group is Docetaxel 75 mg/m\^2 Q3W plus carboplatin AUC 5 Q3W.

03

Conditions studied

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Peritoneal Neoplasms

Keywords

  • Programmed Cell Death-1 (PD1, PD-1)
  • Programmed Death-Ligand 1 (PDL1, PD-L1)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has confirmed International Federation of Gynecology and Obstetrics (FIGO) Stage III or Stage IV EOC (high-grade predominantly serous, endometrioid (any grade), carcinosarcoma, mixed mullerian with high-grade serous component, clear cell, or low-grade serous OC), primary peritoneal cancer, or fallopian tube cancer
  • Has just completed primary debulking surgery or is eligible for primary debulking surgery or is a potential candidate for interval debulking surgery
  • Is a candidate for carboplatin and paclitaxel chemotherapy, to be administered in the or neoadjuvant setting
  • Candidates for neoadjuvant chemotherapy, has a cancer antigen 125 (CA-125) (kilounits/L):carcinoembryonic antigen (CEA; ng/mL) ratio greater than or equal to 25
  • Is able to provide a newly obtained core or excisional of a tumor lesion for prospective testing of BRCA1/2 and Programmed Cell Death-Ligand 1 () tumor markers status prior to randomization
  • Has an (ECOG) performance status of 0 or 1, as assessed within 7 days prior to initiating chemotherapy in the lead-in period and within 3 days prior to Day 1 of Cycle 1
  • Female participants are not pregnant, not breastfeeding, and at least 1 of the following conditions applies: a.) Not a woman of (WOCBP) OR b.) Is a WOCBP and using a method that is highly effective, with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle, during the Treatment Period and for at least 120 days following the last dose of pembrolizumab (or pembrolizumab placebo) and bevacizumab (if administered), at least 180 days following the last dose of olaparib (or olaparib placebo), and at least 210 days following the last dose of chemotherapy and agrees not to donate eggs (ova, oocytes) to others or freeze/store for her own use for the purpose of reproduction during this period. The investigator should evaluate the potential for contraceptive method failure in relationship to the first dose of study treatment. A WOCBP must have a negative highly sensitive pregnancy test within either 24 hours (urine) or 72 hours (serum) before the first dose of study treatment. If a urine test cannot be confirmed as negative, a serum pregnancy test is required. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy. Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
  • Has adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Has mucinous, germ cell, or borderline tumor of the ovary
  • Has a known or suspected deleterious mutation (germline or somatic) in either BRCA1 or BRCA2
  • Has a history of non-infectious pneumonitis that required treatment with or currently has pneumonitis
  • Has either myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or has features suggestive of MDS/AML
  • Has a known additional that is progressing or has required active treatment in the last 3 years Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. ductal carcinoma in situ, cervical carcinoma in situ) that has undergone potentially curative therapy are not excluded.
  • Has ongoing Grade 3 or Grade 4 toxicity, excluding alopecia, following chemotherapy administered during the lead-in period
  • Has known active central nervous system and/or carcinomatous meningitis. Participants with may participate provided they were previously treated (except with chemotherapy) and are radiologically stable, clinically stable, and no steroids were used for the management of symptoms related to brain metastases within 14 days prior to randomization. Stable brain metastases should be established prior to the first dose of study medication lead-in chemotherapy
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (dosing >10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to randomization
  • Has an active disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs) Note: Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
  • Has a known history of active tuberculosis (TB; Bacillus Tuberculosis)
  • Has an active infection requiring systemic therapy
  • Has received colony-stimulating factors (eg, granulocyte colony stimulating factor [G-CSF], granulocyte macrophage colony-stimulating factor [GM-CSF] or recombinant erythropoietin) within 4 weeks prior to receiving chemotherapy during the lead-in period
  • Is considered to be of poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection
  • Has had surgery to treat borderline tumors, early stage EOC, or early stage fallopian tube cancer \<6 months prior to screening
  • Has a known history of (HIV) infection
  • Has a known history of (defined as hepatitis B surface antigen [HBsAg] reactive) or known active virus (defined as HCV RNA [qualitative] is detected) infection. Testing for hepatitis B or hepatitis C is required at screening only if mandated by local health authority. Note: Participants with a history of hepatitis B but who are HBsAg negative are eligible for the study
  • Is either unable to swallow orally administered medication or has a gastrointestinal (GI) disorder affecting absorption (e.g. gastrectomy, partial bowel obstruction, malabsorption)
  • Has uncontrolled hypertension
  • Has current, bowel obstruction (including sub-occlusive disease), abdominal fistula or GI perforation, related to underlying EOC (for participants receiving bevacizumab)
  • Has a history of hemorrhage, hemoptysis or active GI bleeding within 6 months prior to randomization (for participants receiving bevacizumab)
  • Is a who has a positive urine pregnancy test within 72 hours before the first dose of chemotherapy in the lead-in period and within 72 hours prior to Day 1 of Cycle 1, is pregnant or breastfeeding, or is expecting to conceive children within the projected duration of the study, starting with screening through 120 days following the last dose of pembrolizumab (or pembrolizumab placebo) and bevacizumab (if administered), at least 180 days following the last dose of olaparib (or olaparib placebo), and at least 210 days following the last dose of chemotherapy
  • Has received prior treatment for any stage of OC, including radiation or systemic anti-cancer therapy (e.g. chemotherapy, hormonal therapy, immunotherapy, therapy)
  • Has received prior therapy with an anti-Programmed Cell Death-1 (), anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T lymphocyte antigen-4 [CTLA-4], OX 40, CD137)
  • Has received prior therapy with either olaparib or any other poly(adenosine-ribose) polymerase (PARP) inhibitor
  • Has intraperitoneal chemotherapy planned or has been administered as therapy
  • Has received a within 30 days prior to the first dose of study treatment on Day 1 of Cycle 1
  • Has severe (≥Grade 3) to pembrolizumab, olaparib, carboplatin, paclitaxel or bevacizumab (if using) and/or any of their
  • Is currently receiving either strong (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate (eg, ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil) inhibitors of cytochrome P450 (CYP)3A4 that cannot be discontinued for the duration of the study
  • Is currently receiving either strong (e.g. phenobarbital, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine, and St John's Wort) or moderate (e.g. bosentan, efavirenz, modafinil) inducers of that cannot be discontinued for the duration of the study
  • Is currently participating or has participated in a study of an investigational agent or has used an investigational device within 4 weeks (28 days) of starting chemotherapy in the Lead-in Period
  • Has resting (ECG) indicating uncontrolled, potentially reversible cardiac conditions or participant has congenital long syndrome
  • Has had an allogenic tissue/solid organ transplant, has received previous allogenic bone-marrow transplant, or has received double umbilical cord transplantation
  • Either has had major surgery within 3 weeks of randomization or has not recovered from any effects of any major surgery
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,367 participants (actual)

Study arms

  • Experimental
    Carboplatin + Paclitaxel + Pembrolizumab + Olaparib

    Participants receive carboplatin/paclitaxel via intravenous (IV) infusion for five 3-week cycles PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS olaparib 300 mg via oral tablet twice each day (BID), starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m\^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.

    Biological: Pembrolizumab · Drug: Carboplatin · Drug: Paclitaxel · Drug: Olaparib · Biological: Bevacizumab · Drug: Docetaxel

  • Experimental
    Carboplatin + Paclitaxel + Pembrolizumab

    Participants receive carboplatin/paclitaxel via IV infusion for five 3-week cycles starting in Cycle 1 PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS placebo for olaparib via oral tablet BID, starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m\^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.

    Biological: Pembrolizumab · Drug: Carboplatin · Drug: Paclitaxel · Drug: Placebo for olaparib · Biological: Bevacizumab · Drug: Docetaxel

  • Active comparator
    Carboplatin + Paclitaxel

    Participants receive carboplatin/paclitaxel via IV infusion for five 3-week cycles PLUS placebo for pembrolizumab (normal saline or dextrose) via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS placebo for olaparib via oral tablet BID, starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m\^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.

    Drug: Placebo for pembrolizumab · Drug: Carboplatin · Drug: Paclitaxel · Drug: Placebo for olaparib · Biological: Bevacizumab · Drug: Docetaxel

Interventions

  • BiologicalPembrolizumab

    IV infusion

    Also known as: MK-3475, KEYTRUDA®

  • DrugPlacebo for pembrolizumab

    IV infusion

    Also known as: normal saline or dextrose

  • IV infusion

    Also known as: PARAPLATIN®

  • IV infusion

    Also known as: TAXOL®

  • Oral tablet

    Also known as: MK-7339, LYNPARZA®

  • DrugPlacebo for olaparib

    Oral tablet

  • BiologicalBevacizumab

    IV infusion

    Also known as: AVASTIN®

  • IV infusion

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS]≥10)

    PFS is defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 based on Investigator assessment or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS per RECIST 1.1 as assessed by the Investigator will be reported for participants with PD-L1 positive tumors (CPS≥10). PFS was calculated using the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to approximately 67 months

  2. PFS Per RECIST 1.1 as Assessed by the Investigator in All Participants

    PFS is defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 based on Investigator assessment or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS per RECIST 1.1 as assessed by the Investigator will be reported for all participants. PFS was calculated using the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to approximately 67 months

Secondary outcomes

  1. Overall Survival (OS) in Participants With PD-L1 Positive Tumors (CPS ≥ 10)

    OS is defined as the time from the date of randomization to death due to any cause. The OS is reported for all participants with PD-L1 positive tumors (CPS≥10). The OS was calculated using the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to approximately 67 months

  2. OS in All Participants

    OS is defined as the time from the date of randomization to death due to any cause. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to approximately 67 months

  3. PFS Per RECIST 1.1 as Assessed by Blinded Independent Central Review (BICR) in Participants With PD-L1 Positive Tumors (CPS≥10)

    PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review assessment or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS per RECIST 1.1 as assessed by blinded independent central review will be reported for participants with PD-L1 positive (CPS≥10) tumors (CPS≥10). PFS was calculated using the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to approximately 66 months

  4. PFS Per RECIST 1.1 as Assessed by BICR in All Participants

    PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review assessment or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS per RECIST 1.1 as assessed by blinded independent central review will be reported for all participants. PFS was calculated using the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to approximately 66 months

  5. PFS After Second-line Treatment (PFS2) Following Discontinuation of Study Treatment as Assessed by the Investigator in Participants With PD-L1 Positive Tumors (CPS≥10)

    PFS2 is defined as the time from randomization until PD after second-line treatment per RECIST 1.1 based on Investigator assessment, or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS2 per RECIST 1.1 as assessed by the Investigator is reported for participants with PD-L1 positive tumors (CPS≥10). PFS2 was calculated using the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to approximately 67 months

  6. PFS2 Following Discontinuation of Study Treatment as Assessed by the Investigator in All Participants

    PFS2 is defined as the time from randomization until PD after second-line treatment per RECIST 1.1 based on Investigator assessment, or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS2 per RECIST 1.1 as assessed by the Investigator is reported for all participants. PFS2 was calculated using the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to approximately 67 months

  7. Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) (GHS/QoL) Combined Score

    The EORTC-QLQ-C30 is a 30-item questionnaire to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question "How would you rate your overall health during the past week?" (Item 29) and the Quality of Life (QoL) question "How would you rate your overall quality of life during the past week?" (Item 30) were scored on a 7-point scale (1=Very Poor; 7=Excellent). Using linear transformation, raw scores were standardized so scores ranged from 0 to 100; higher score = better outcome. Change from baseline to Week 45 in EORTC QLQ-C30 Items 29 and 30 combined scores was calculated based on a constrained longitudinal data analysis (cLDA) with scores as response variable; covariates for treatment by time interaction and stratification factors (debulking surgery \[planned interval vs R0 following primary vs R1 following primary\], and bevacizumab use \[Yes vs No\], and PD-L1 CPS \[\<10 vs ≥10\]).

    Time frame: Baseline and week 45

  8. Mean Change From Baseline in Abdominal and Gastrointestinal (Abdominal/GI) Symptoms Score Using the EORTC Quality of Life Questionnaire-Ovarian Cancer (QLQ-OV28) Abdominal/GI Symptom Scale

    Participant responses to 6 questions from the EORTC QoL Questionnaire-Ovarian Cancer (QLQ-OV28) abdominal/GI symptom scale about abdominal pain, bloated feeling in abdomen/stomach, changes in clothing fit, changes in bowel habit, flatulence, and stomach fullness when eating (questions 31-36) were scored on a 4-point scale (1=Not at all; 4=Very much); lower score = better abdominal/GI symptoms. Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100; a lower score indicating a better overall outcome. Change from baseline to Week 45 in EORTC QLQ-OV28 Items 31-36 combined scores was calculated based on a constrained longitudinal data analysis (cLDA) model with scores as response variable; covariates for treatment by time interaction and stratification factors (debulking surgery \[planned interval vs R0 following primary vs R1 following primary\], and bevacizumab use \[Yes vs No\], and PD-L1 CPS \[\<10 vs ≥10\]).

    Time frame: Baseline and week 45

  9. Time to Deterioration (TTD) in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score

    The EORTC-QLQ-C30 is a 30-item questionnaire to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question "How would you rate your overall health during the past week?" (Item 29) and the Quality of Life (QoL) question "How would you rate your overall quality of life during the past week?" (Item 30) were scored on a 7-point scale (1=Very Poor; 7=Excellent). Using linear transformation, raw scores were standardized so scores ranged from 0 to 100; higher score = better outcome. TTD is defined as the time from the first EORTC QLQ-C30 Items 29 and 30 combined scores to deterioration (defined as ≥10-point decrease in GHS/QoL score from baseline with confirmation under right-censoring rule \[the last observation\]) or death, whichever occurs first. TTD was calculated using the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to approximately 31 months

  10. Time to Deterioration (TTD) of Abdominal/GI Symptoms Using EORTC QLQ-OV28

    Participant responses to 6 questions from the EORTC QoL Questionnaire-Ovarian Cancer (QLQ-OV28) abdominal/GI symptom scale about abdominal pain, bloated feeling in abdomen/stomach, changes in clothing fit, changes in bowel habit, flatulence, and stomach fullness when eating (questions 31-36) were scored on a 4-point scale (1=Not at all; 4=Very much); lower score = better abdominal/GI symptoms. Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100; a lower score indicating a better overall outcome. TTD is defined as the time from the first EORTC QLQ-OV28 questions 31-36 combined scores to deterioration (defined as ≥10-point decrease in abdominal/GI symptoms score from baseline with confirmation under right-censoring rule \[the last observation\]) or death, whichever occurs first. TTD was calculated using the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to approximately 31 months

  11. Time to First Subsequent Anti-cancer Treatment (TFST) in Participants With PD-L1 Positive Tumors (CPS≥10)

    TFST is defined as the time from randomization to initiation of first subsequent anti-cancer treatment or death due to any cause, whichever occurs first. The TFST was determined from the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to approximately 67 months

  12. Time to First Subsequent Anti-cancer Treatment (TFST) in All Participants

    TFST is defined as the time from randomization to initiation of first subsequent anti-cancer treatment or death due to any cause, whichever occurs first. The TFST was determined from the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to approximately 67 months

  13. Time to Second Subsequent Anti-cancer Treatment (TSST) in Participants With PD-L1 Positive Tumors (CPS≥10)

    TSST is defined as the time from randomization to initiation of second subsequent anti-cancer treatment or death due to any cause, whichever occurs first. The TSST was determined from the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to approximately 67 months

  14. Time to Second Subsequent Anti-cancer Treatment (TSST) in All Participants

    TSST is defined as the time from randomization to initiation of second subsequent anti-cancer treatment or death due to any cause, whichever occurs first. The TSST was determined from the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to approximately 67 months

  15. Time to Discontinuation of Study Treatment or Death (TDT) in Participants With PD-L1 Positive Tumors (CPS≥10)

    TDT is defined as the time from the date of randomization to discontinuation of study treatment or death due to any cause, whichever occurs first. The TDT was determined from the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to approximately 67 months

  16. Time to Discontinuation of Study Treatment or Death (TDT) in All Participants

    TDT is defined as the time from the date of randomization to discontinuation of study treatment or death due to any cause, whichever occurs first. The TDT was determined from the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to approximately 67 months

  17. Pathological Complete Response (pCR) Rate in Participants With PD-L1 Positive Tumors (CPS≥10)

    pCR is defined as the disappearance of all known disease noted prior to surgery; all surgical specimens collected during the interval debulking surgery are microscopically negative for malignancy. The percentage of participants who experience pCR was determined based on Miettinen \& Nurminen method stratified by Bevacizumab use (yes versus no).

    Time frame: Up to approximately 21 months

  18. Pathological Complete Response (pCR) Rate in All Participants

    pCR is defined as the disappearance of all known disease noted prior to surgery; all surgical specimens collected during the interval debulking surgery are microscopically negative for malignancy. The percentage of participants who experience pCR was determined based on Miettinen \& Nurminen method stratified by Bevacizumab use (yes versus no) and PD-L1 status (CPS \<10 versus CPS\>=10).

    Time frame: Up to approximately 26 months

  19. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 73 months (anticipated)

  20. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

    Time frame: Up to approximately 6 years (anticipated)

07

Results

Posted Sep 12, 2025

Participant flow

Participant flow — Overall Study
MilestoneCarboplatin + Paclitaxel + Pembrolizumab + OlaparibCarboplatin + Paclitaxel + PembrolizumabCarboplatin + Paclitaxel
Started455458454
Treated452456454
Completed000
Not completed455458454
Withdrew: Death232242229
Withdrew: Lost to follow-up001
Withdrew: Withdrawal by subject743
Withdrew: Ongoing in study216212221

Outcome measures

PrimaryProgression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS]≥10)

PFS is defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 based on Investigator assessment or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS per RECIST 1.1 as assessed by the Investigator will be reported for participants with PD-L1 positive tumors (CPS≥10). PFS was calculated using the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to approximately 67 months
Reported as:
Median · Months
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS]≥10)
MonthsCarboplatin + Paclitaxel + Pembrolizumab + OlaparibCarboplatin + Paclitaxel + PembrolizumabCarboplatin + Paclitaxel
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS]≥10)23.9 (21.0 to 30.2)17.3 (15.2 to 19.4)15.2 (12.5 to 17.2)
Statistical analysis
  • Carboplatin + Paclitaxel + Pembrolizumab + Olaparib vs Carboplatin + Paclitaxel · Log Rank · p = 0.0002 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)) · Hazard ratio (hr): 0.66 · 95% CI 0.53 to 0.83Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)
  • Carboplatin + Paclitaxel + Pembrolizumab vs Carboplatin + Paclitaxel · Log Rank · p = 0.3339 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)) · Hazard ratio (hr): 0.95 · 95% CI 0.77 to 1.19Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)
PrimaryPFS Per RECIST 1.1 as Assessed by the Investigator in All Participants

PFS is defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 based on Investigator assessment or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS per RECIST 1.1 as assessed by the Investigator will be reported for all participants. PFS was calculated using the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to approximately 67 months
Reported as:
Median · Months
PFS Per RECIST 1.1 as Assessed by the Investigator in All Participants
MonthsCarboplatin + Paclitaxel + Pembrolizumab + OlaparibCarboplatin + Paclitaxel + PembrolizumabCarboplatin + Paclitaxel
PFS Per RECIST 1.1 as Assessed by the Investigator in All Participants22.2 (18.8 to 24.7)15.2 (13.6 to 16.4)14.6 (12.7 to 16.3)
Statistical analysis
  • Carboplatin + Paclitaxel + Pembrolizumab + Olaparib vs Carboplatin + Paclitaxel · Log Rank · p = <0.0001 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)) · Hazard ratio (hr): 0.71 · 95% CI 0.61 to 0.84Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)
  • Carboplatin + Paclitaxel + Pembrolizumab vs Carboplatin + Paclitaxel · Log Rank · p = 0.5527 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)) · Hazard ratio (hr): 1.01 · 95% CI 0.87 to 1.18Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)
SecondaryOverall Survival (OS) in Participants With PD-L1 Positive Tumors (CPS ≥ 10)

OS is defined as the time from the date of randomization to death due to any cause. The OS is reported for all participants with PD-L1 positive tumors (CPS≥10). The OS was calculated using the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to approximately 67 months
Reported as:
Median · Months
Overall Survival (OS) in Participants With PD-L1 Positive Tumors (CPS ≥ 10)
MonthsCarboplatin + Paclitaxel + Pembrolizumab + OlaparibCarboplatin + Paclitaxel + PembrolizumabCarboplatin + Paclitaxel
Overall Survival (OS) in Participants With PD-L1 Positive Tumors (CPS ≥ 10)50.2 (43.9 to NA)56.4 (42.4 to NA)51.6 (41.8 to NA)
Statistical analysis
  • Carboplatin + Paclitaxel + Pembrolizumab + Olaparib vs Carboplatin + Paclitaxel · Log Rank · p = 0.4314 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)) · Hazard ratio (hr): 0.98 · 95% CI 0.75 to 1.27Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)
  • Carboplatin + Paclitaxel + Pembrolizumab vs Carboplatin + Paclitaxel · Log Rank · p = 0.3107 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)) · Hazard ratio (hr): 0.94 · 95% CI 0.72 to 1.22Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)
SecondaryOS in All Participants

OS is defined as the time from the date of randomization to death due to any cause. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to approximately 67 months
Reported as:
Median · Months
OS in All Participants
MonthsCarboplatin + Paclitaxel + Pembrolizumab + OlaparibCarboplatin + Paclitaxel + PembrolizumabCarboplatin + Paclitaxel
OS in All Participants47.7 (42.3 to 54.9)44.2 (38.1 to 52.2)47.1 (41.7 to 60.9)
Statistical analysis
  • Carboplatin + Paclitaxel + Pembrolizumab + Olaparib vs Carboplatin + Paclitaxel · Log Rank · p = 0.6716 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)) · Hazard ratio (hr): 1.04 · 95% CI 0.87 to 1.25Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)
  • Carboplatin + Paclitaxel + Pembrolizumab vs Carboplatin + Paclitaxel · Log Rank · p = 0.7448 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)) · Hazard ratio (hr): 1.06 · 95% CI 0.89 to 1.27Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)
SecondaryPFS Per RECIST 1.1 as Assessed by Blinded Independent Central Review (BICR) in Participants With PD-L1 Positive Tumors (CPS≥10)

PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review assessment or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS per RECIST 1.1 as assessed by blinded independent central review will be reported for participants with PD-L1 positive (CPS≥10) tumors (CPS≥10). PFS was calculated using the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to approximately 66 months
Reported as:
Median · Months
PFS Per RECIST 1.1 as Assessed by Blinded Independent Central Review (BICR) in Participants With PD-L1 Positive Tumors (CPS≥10)
MonthsCarboplatin + Paclitaxel + Pembrolizumab + OlaparibCarboplatin + Paclitaxel + PembrolizumabCarboplatin + Paclitaxel
PFS Per RECIST 1.1 as Assessed by Blinded Independent Central Review (BICR) in Participants With PD-L1 Positive Tumors (CPS≥10)42.0 (27.2 to 51.9)20.3 (17.3 to 27.4)22.1 (15.4 to 29.5)
Statistical analysis
  • Carboplatin + Paclitaxel + Pembrolizumab + Olaparib vs Carboplatin + Paclitaxel · Log Rank · p = 0.0012 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)) · Hazard ratio (hr): 0.65 · 95% CI 0.50 to 0.86Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)
  • Carboplatin + Paclitaxel + Pembrolizumab vs Carboplatin + Paclitaxel · Log Rank · p = 0.4366 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)) · Hazard ratio (hr): 0.98 · 95% CI 0.75 to 1.27Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)
SecondaryPFS Per RECIST 1.1 as Assessed by BICR in All Participants

PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review assessment or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS per RECIST 1.1 as assessed by blinded independent central review will be reported for all participants. PFS was calculated using the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to approximately 66 months
Reported as:
Median · Months
PFS Per RECIST 1.1 as Assessed by BICR in All Participants
MonthsCarboplatin + Paclitaxel + Pembrolizumab + OlaparibCarboplatin + Paclitaxel + PembrolizumabCarboplatin + Paclitaxel
PFS Per RECIST 1.1 as Assessed by BICR in All Participants30.1 (24.0 to 37.3)19.0 (16.6 to 22.2)20.8 (16.9 to 25.3)
Statistical analysis
  • Carboplatin + Paclitaxel + Pembrolizumab + Olaparib vs Carboplatin + Paclitaxel · Log Rank · p = 0.0008 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)) · Hazard ratio (hr): 0.74 · 95% CI 0.61 to 0.89Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)
  • Carboplatin + Paclitaxel + Pembrolizumab vs Carboplatin + Paclitaxel · Log Rank · p = 0.7174 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)) · Hazard ratio (hr): 1.05 · 95% CI 0.88 to 1.27Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)
SecondaryPFS After Second-line Treatment (PFS2) Following Discontinuation of Study Treatment as Assessed by the Investigator in Participants With PD-L1 Positive Tumors (CPS≥10)

PFS2 is defined as the time from randomization until PD after second-line treatment per RECIST 1.1 based on Investigator assessment, or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS2 per RECIST 1.1 as assessed by the Investigator is reported for participants with PD-L1 positive tumors (CPS≥10). PFS2 was calculated using the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to approximately 67 months
Reported as:
Median · Months
PFS After Second-line Treatment (PFS2) Following Discontinuation of Study Treatment as Assessed by the Investigator in Participants With PD-L1 Positive Tumors (CPS≥10)
MonthsCarboplatin + Paclitaxel + Pembrolizumab + OlaparibCarboplatin + Paclitaxel + PembrolizumabCarboplatin + Paclitaxel
PFS After Second-line Treatment (PFS2) Following Discontinuation of Study Treatment as Assessed by the Investigator in Participants With PD-L1 Positive Tumors (CPS≥10)41.1 (32.3 to 52.1)34.1 (29.0 to 41.2)29.9 (25.3 to 37.6)
Statistical analysis
  • Carboplatin + Paclitaxel + Pembrolizumab + Olaparib vs Carboplatin + Paclitaxel · Log Rank · p = 0.0228 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)) · Hazard ratio (hr): 0.78 · 95% CI 0.62 to 1.00Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)
  • Carboplatin + Paclitaxel + Pembrolizumab vs Carboplatin + Paclitaxel · Log Rank · p = 0.3935 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)) · Hazard ratio (hr): 0.97 · 95% CI 0.77 to 1.22Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)
SecondaryPFS2 Following Discontinuation of Study Treatment as Assessed by the Investigator in All Participants

PFS2 is defined as the time from randomization until PD after second-line treatment per RECIST 1.1 based on Investigator assessment, or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS2 per RECIST 1.1 as assessed by the Investigator is reported for all participants. PFS2 was calculated using the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to approximately 67 months
Reported as:
Median · Months
PFS2 Following Discontinuation of Study Treatment as Assessed by the Investigator in All Participants
MonthsCarboplatin + Paclitaxel + Pembrolizumab + OlaparibCarboplatin + Paclitaxel + PembrolizumabCarboplatin + Paclitaxel
PFS2 Following Discontinuation of Study Treatment as Assessed by the Investigator in All Participants33.1 (29.9 to 38.5)27.8 (26.0 to 32.5)28.9 (25.4 to 34.2)
Statistical analysis
  • Carboplatin + Paclitaxel + Pembrolizumab + Olaparib vs Carboplatin + Paclitaxel · Log Rank · p = 0.0573 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)) · Hazard ratio (hr): 0.88 · 95% CI 0.74 to 1.03Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)
  • Carboplatin + Paclitaxel + Pembrolizumab vs Carboplatin + Paclitaxel · Log Rank · p = 0.7234 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)) · Hazard ratio (hr): 1.05 · 95% CI 0.89 to 1.23Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)
SecondaryChange From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) (GHS/QoL) Combined Score

The EORTC-QLQ-C30 is a 30-item questionnaire to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question "How would you rate your overall health during the past week?" (Item 29) and the Quality of Life (QoL) question "How would you rate your overall quality of life during the past week?" (Item 30) were scored on a 7-point scale (1=Very Poor; 7=Excellent). Using linear transformation, raw scores were standardized so scores ranged from 0 to 100; higher score = better outcome. Change from baseline to Week 45 in EORTC QLQ-C30 Items 29 and 30 combined scores was calculated based on a constrained longitudinal data analysis (cLDA) with scores as response variable; covariates for treatment by time interaction and stratification factors (debulking surgery \[planned interval vs R0 following primary vs R1 following primary\], and bevacizumab use \[Yes vs No\], and PD-L1 CPS \[\<10 vs ≥10\]).

Time frame:
Baseline and week 45
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) (GHS/QoL) Combined Score
Score on a ScaleCarboplatin + Paclitaxel + Pembrolizumab + OlaparibCarboplatin + Paclitaxel + PembrolizumabCarboplatin + Paclitaxel
cLDA model using Carboplatin+Paclitaxel+Pembrolizumab+Olaparib and Carboplatin+Paclitaxel arms0.45 (-1.62 to 2.52)—0.18 (-1.87 to 2.24)
cLDA model using Carboplatin+Paclitaxel+Pembrolizumab and Carboplatin+Paclitaxel arms—-0.49 (-2.63 to 1.65)0.61 (-1.48 to 2.70)
Statistical analysis
  • Carboplatin + Paclitaxel + Pembrolizumab + Olaparib vs Carboplatin + Paclitaxel · t-test, 2 sided · p = 0.8481 · Difference in least squares means (lsm): 0.26 · 95% CI -2.44 to 2.97Based on cLDA model with scores as response variable; covariates for treatment by time interaction and stratification factors (debulking surgery \[planned interval vs R0 following primary vs R1 following primary\], bevacizumab use, and PD-L1 CPS)
  • Carboplatin + Paclitaxel + Pembrolizumab vs Carboplatin + Paclitaxel · t-test, 2 sided · p = 0.4335 · Difference in ls means: -1.10 · 95% CI -3.87 to 1.66Based on cLDA model with scores as response variable; covariates for treatment by time interaction and stratification factors (debulking surgery \[planned interval vs R0 following primary vs R1 following primary\], bevacizumab use, and PD-L1 CPS)
SecondaryMean Change From Baseline in Abdominal and Gastrointestinal (Abdominal/GI) Symptoms Score Using the EORTC Quality of Life Questionnaire-Ovarian Cancer (QLQ-OV28) Abdominal/GI Symptom Scale

Participant responses to 6 questions from the EORTC QoL Questionnaire-Ovarian Cancer (QLQ-OV28) abdominal/GI symptom scale about abdominal pain, bloated feeling in abdomen/stomach, changes in clothing fit, changes in bowel habit, flatulence, and stomach fullness when eating (questions 31-36) were scored on a 4-point scale (1=Not at all; 4=Very much); lower score = better abdominal/GI symptoms. Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100; a lower score indicating a better overall outcome. Change from baseline to Week 45 in EORTC QLQ-OV28 Items 31-36 combined scores was calculated based on a constrained longitudinal data analysis (cLDA) model with scores as response variable; covariates for treatment by time interaction and stratification factors (debulking surgery \[planned interval vs R0 following primary vs R1 following primary\], and bevacizumab use \[Yes vs No\], and PD-L1 CPS \[\<10 vs ≥10\]).

Time frame:
Baseline and week 45
Reported as:
Least squares mean · Score on a Scale
Mean Change From Baseline in Abdominal and Gastrointestinal (Abdominal/GI) Symptoms Score Using the EORTC Quality of Life Questionnaire-Ovarian Cancer (QLQ-OV28) Abdominal/GI Symptom Scale
Score on a ScaleCarboplatin + Paclitaxel + Pembrolizumab + OlaparibCarboplatin + Paclitaxel + PembrolizumabCarboplatin + Paclitaxel
cLDA model using Carboplatin+Paclitaxel+Pembrolizumab+Olaparib and Carboplatin+Paclitaxel arms-2.63 (-4.40 to -0.85)—-2.77 (-4.54 to -1.00)
cLDA model using Carboplatin+Paclitaxel+Pembrolizumab and Carboplatin+Paclitaxel arms—-2.66 (-4.50 to -0.82)-2.58 (-4.38 to -0.79)
Statistical analysis
  • Carboplatin + Paclitaxel + Pembrolizumab + Olaparib vs Carboplatin + Paclitaxel · t-test, 2 sided · p = 0.9024 · Difference in least squares means (lsm): 0.14 · 95% CI -2.15 to 2.44Based on cLDA model with scores as response variable; covariates for treatment by time interaction and stratification factors (debulking surgery \[planned interval vs R0 following primary vs R1 following primary\], bevacizumab use, and PD-L1 CPS)
  • Carboplatin + Paclitaxel + Pembrolizumab vs Carboplatin + Paclitaxel · t-test, 2 sided · p = 0.9478 · Difference in least squares means (lsm): -0.08 · 95% CI -2.47 to 2.31Based on cLDA model with scores as response variable; covariates for treatment by time interaction and stratification factors (debulking surgery \[planned interval vs R0 following primary vs R1 following primary\], bevacizumab use, and PD-L1 CPS)
SecondaryTime to Deterioration (TTD) in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score

The EORTC-QLQ-C30 is a 30-item questionnaire to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question "How would you rate your overall health during the past week?" (Item 29) and the Quality of Life (QoL) question "How would you rate your overall quality of life during the past week?" (Item 30) were scored on a 7-point scale (1=Very Poor; 7=Excellent). Using linear transformation, raw scores were standardized so scores ranged from 0 to 100; higher score = better outcome. TTD is defined as the time from the first EORTC QLQ-C30 Items 29 and 30 combined scores to deterioration (defined as ≥10-point decrease in GHS/QoL score from baseline with confirmation under right-censoring rule \[the last observation\]) or death, whichever occurs first. TTD was calculated using the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to approximately 31 months
Reported as:
Median · Months
Time to Deterioration (TTD) in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
MonthsCarboplatin + Paclitaxel + Pembrolizumab + OlaparibCarboplatin + Paclitaxel + PembrolizumabCarboplatin + Paclitaxel
Time to Deterioration (TTD) in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined ScoreNA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Carboplatin + Paclitaxel + Pembrolizumab + Olaparib vs Carboplatin + Paclitaxel · Log Rank · p = 0.2644 (One-sided p-value based on log-rank test stratified by surgery (planned interval debulking versus R0 following primary debulking versus R1 following primary debulking), bevacizumab use (yes versus no), and PD-L1 status (CPS\<10 vs CPS≥10).) · Hazard ratio (hr): 0.92 · 95% CI 0.73 to 1.17Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by surgery (planned interval vs R0 following primary vs R1 following primary debulking), bevacizumab use (Yes vs No), PD-L1 status (CPS\<10 vs CPS≥10)
  • Carboplatin + Paclitaxel + Pembrolizumab vs Carboplatin + Paclitaxel · Log Rank · p = 0.1953 (One-sided p-value based on log-rank test stratified by surgery (planned interval debulking versus R0 following primary debulking versus R1 following primary debulking), bevacizumab use (yes versus no), and PD-L1 status (CPS\<10 vs CPS≥10).) · Hazard ratio (hr): 0.90 · 95% CI 0.71 to 1.14Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by surgery (planned interval vs R0 following primary vs R1 following primary debulking), bevacizumab use (Yes vs No), PD-L1 status (CPS\<10 vs CPS≥10)
SecondaryTime to Deterioration (TTD) of Abdominal/GI Symptoms Using EORTC QLQ-OV28

Participant responses to 6 questions from the EORTC QoL Questionnaire-Ovarian Cancer (QLQ-OV28) abdominal/GI symptom scale about abdominal pain, bloated feeling in abdomen/stomach, changes in clothing fit, changes in bowel habit, flatulence, and stomach fullness when eating (questions 31-36) were scored on a 4-point scale (1=Not at all; 4=Very much); lower score = better abdominal/GI symptoms. Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100; a lower score indicating a better overall outcome. TTD is defined as the time from the first EORTC QLQ-OV28 questions 31-36 combined scores to deterioration (defined as ≥10-point decrease in abdominal/GI symptoms score from baseline with confirmation under right-censoring rule \[the last observation\]) or death, whichever occurs first. TTD was calculated using the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to approximately 31 months
Reported as:
Median · Months
Time to Deterioration (TTD) of Abdominal/GI Symptoms Using EORTC QLQ-OV28
MonthsCarboplatin + Paclitaxel + Pembrolizumab + OlaparibCarboplatin + Paclitaxel + PembrolizumabCarboplatin + Paclitaxel
Time to Deterioration (TTD) of Abdominal/GI Symptoms Using EORTC QLQ-OV28NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Carboplatin + Paclitaxel + Pembrolizumab + Olaparib vs Carboplatin + Paclitaxel · Log Rank · p = 0.5188 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)) · Hazard ratio (hr): 1.01 · 95% CI 0.77 to 1.30Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)
  • Carboplatin + Paclitaxel + Pembrolizumab vs Carboplatin + Paclitaxel · Log Rank · p = 0.5091 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)) · Hazard ratio (hr): 1.00 · 95% CI 0.77 to 1.30Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)
SecondaryTime to First Subsequent Anti-cancer Treatment (TFST) in Participants With PD-L1 Positive Tumors (CPS≥10)

TFST is defined as the time from randomization to initiation of first subsequent anti-cancer treatment or death due to any cause, whichever occurs first. The TFST was determined from the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to approximately 67 months
Reported as:
Median · Months
Time to First Subsequent Anti-cancer Treatment (TFST) in Participants With PD-L1 Positive Tumors (CPS≥10)
MonthsCarboplatin + Paclitaxel + Pembrolizumab + OlaparibCarboplatin + Paclitaxel + PembrolizumabCarboplatin + Paclitaxel
Time to First Subsequent Anti-cancer Treatment (TFST) in Participants With PD-L1 Positive Tumors (CPS≥10)29.3 (24.0 to 33.8)22.2 (17.7 to 25.4)17.7 (14.1 to 21.4)
Statistical analysis
  • Carboplatin + Paclitaxel + Pembrolizumab + Olaparib vs Carboplatin + Paclitaxel · Log Rank · p = <0.0001 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)) · Hazard ratio (hr): 0.63 · 95% CI 0.51 to 0.79Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)
  • Carboplatin + Paclitaxel + Pembrolizumab vs Carboplatin + Paclitaxel · Log Rank · p = 0.0981 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)) · Hazard ratio (hr): 0.87 · 95% CI 0.70 to 1.08Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)
SecondaryTime to First Subsequent Anti-cancer Treatment (TFST) in All Participants

TFST is defined as the time from randomization to initiation of first subsequent anti-cancer treatment or death due to any cause, whichever occurs first. The TFST was determined from the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to approximately 67 months
Reported as:
Median · Months
Time to First Subsequent Anti-cancer Treatment (TFST) in All Participants
MonthsCarboplatin + Paclitaxel + Pembrolizumab + OlaparibCarboplatin + Paclitaxel + PembrolizumabCarboplatin + Paclitaxel
Time to First Subsequent Anti-cancer Treatment (TFST) in All Participants24.9 (22.0 to 29.5)18.2 (16.8 to 21.0)17.2 (15.3 to 19.0)
Statistical analysis
  • Carboplatin + Paclitaxel + Pembrolizumab + Olaparib vs Carboplatin + Paclitaxel · Log Rank · p = <0.0001 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)) · Hazard ratio (hr): 0.69 · 95% CI 0.59 to 0.80Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)
  • Carboplatin + Paclitaxel + Pembrolizumab vs Carboplatin + Paclitaxel · Log Rank · p = 0.1206 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)) · Hazard ratio (hr): 0.92 · 95% CI 0.79 to 1.06Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)
SecondaryTime to Second Subsequent Anti-cancer Treatment (TSST) in Participants With PD-L1 Positive Tumors (CPS≥10)

TSST is defined as the time from randomization to initiation of second subsequent anti-cancer treatment or death due to any cause, whichever occurs first. The TSST was determined from the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to approximately 67 months
Reported as:
Median · Months
Time to Second Subsequent Anti-cancer Treatment (TSST) in Participants With PD-L1 Positive Tumors (CPS≥10)
MonthsCarboplatin + Paclitaxel + Pembrolizumab + OlaparibCarboplatin + Paclitaxel + PembrolizumabCarboplatin + Paclitaxel
Time to Second Subsequent Anti-cancer Treatment (TSST) in Participants With PD-L1 Positive Tumors (CPS≥10)43.9 (33.5 to 52.5)36.3 (31.9 to 42.8)32.3 (27.5 to 39.2)
Statistical analysis
  • Carboplatin + Paclitaxel + Pembrolizumab + Olaparib vs Carboplatin + Paclitaxel · Log Rank · p = 0.0316 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)) · Hazard ratio (hr): 0.80 · 95% CI 0.63 to 1.01Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)
  • Carboplatin + Paclitaxel + Pembrolizumab vs Carboplatin + Paclitaxel · Log Rank · p = 0.4441 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)) · Hazard ratio (hr): 0.98 · 95% CI 0.78 to 1.24Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)
SecondaryTime to Second Subsequent Anti-cancer Treatment (TSST) in All Participants

TSST is defined as the time from randomization to initiation of second subsequent anti-cancer treatment or death due to any cause, whichever occurs first. The TSST was determined from the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to approximately 67 months
Reported as:
Median · Months
Time to Second Subsequent Anti-cancer Treatment (TSST) in All Participants
MonthsCarboplatin + Paclitaxel + Pembrolizumab + OlaparibCarboplatin + Paclitaxel + PembrolizumabCarboplatin + Paclitaxel
Time to Second Subsequent Anti-cancer Treatment (TSST) in All Participants34.7 (31.3 to 40.4)31.3 (28.1 to 34.2)30.9 (27.2 to 35.1)
Statistical analysis
  • Carboplatin + Paclitaxel + Pembrolizumab + Olaparib vs Carboplatin + Paclitaxel · Log Rank · p = 0.0853 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)) · Hazard ratio (hr): 0.89 · 95% CI 0.76 to 1.05Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)
  • Carboplatin + Paclitaxel + Pembrolizumab vs Carboplatin + Paclitaxel · Log Rank · p = 0.7165 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)) · Hazard ratio (hr): 1.05 · 95% CI 0.89 to 1.23Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)
SecondaryTime to Discontinuation of Study Treatment or Death (TDT) in Participants With PD-L1 Positive Tumors (CPS≥10)

TDT is defined as the time from the date of randomization to discontinuation of study treatment or death due to any cause, whichever occurs first. The TDT was determined from the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to approximately 67 months
Reported as:
Median · Months
Time to Discontinuation of Study Treatment or Death (TDT) in Participants With PD-L1 Positive Tumors (CPS≥10)
MonthsCarboplatin + Paclitaxel + Pembrolizumab + OlaparibCarboplatin + Paclitaxel + PembrolizumabCarboplatin + Paclitaxel
Time to Discontinuation of Study Treatment or Death (TDT) in Participants With PD-L1 Positive Tumors (CPS≥10)18.9 (14.9 to 22.4)15.3 (12.6 to 17.3)15.3 (13.0 to 17.3)
Statistical analysis
  • Carboplatin + Paclitaxel + Pembrolizumab + Olaparib vs Carboplatin + Paclitaxel · Log Rank · p = 0.1029 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)) · Hazard ratio (hr): 0.87 · 95% CI 0.71 to 1.08Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)
  • Carboplatin + Paclitaxel + Pembrolizumab vs Carboplatin + Paclitaxel · Log Rank · p = 0.8231 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)) · Hazard ratio (hr): 1.10 · 95% CI 0.90 to 1.36Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary) and bevacizumab use (Yes vs No)
SecondaryTime to Discontinuation of Study Treatment or Death (TDT) in All Participants

TDT is defined as the time from the date of randomization to discontinuation of study treatment or death due to any cause, whichever occurs first. The TDT was determined from the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to approximately 67 months
Reported as:
Median · Months
Time to Discontinuation of Study Treatment or Death (TDT) in All Participants
MonthsCarboplatin + Paclitaxel + Pembrolizumab + OlaparibCarboplatin + Paclitaxel + PembrolizumabCarboplatin + Paclitaxel
Time to Discontinuation of Study Treatment or Death (TDT) in All Participants17.7 (15.7 to 19.5)14.1 (12.4 to 15.4)15.2 (13.6 to 16.6)
Statistical analysis
  • Carboplatin + Paclitaxel + Pembrolizumab + Olaparib vs Carboplatin + Paclitaxel · Log Rank · p = 0.0442 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)) · Hazard ratio (hr): 0.88 · 95% CI 0.76 to 1.02Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)
  • Carboplatin + Paclitaxel + Pembrolizumab vs Carboplatin + Paclitaxel · Log Rank · p = 0.9565 (One-sided p-value based on log-rank test stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)) · Hazard ratio (hr): 1.14 · 95% CI 0.98 to 1.31Based on Cox regression model with Efron's method of tie handling; treatment as covariate stratified by debulking surgery (planned interval vs R0 following primary vs R1 following primary), bevacizumab use (Yes vs No), and PD-L1 CPS (\<10 vs ≥10)
SecondaryPathological Complete Response (pCR) Rate in Participants With PD-L1 Positive Tumors (CPS≥10)

pCR is defined as the disappearance of all known disease noted prior to surgery; all surgical specimens collected during the interval debulking surgery are microscopically negative for malignancy. The percentage of participants who experience pCR was determined based on Miettinen \& Nurminen method stratified by Bevacizumab use (yes versus no).

Time frame:
Up to approximately 21 months
Reported as:
Number · Percentage of Participants
Pathological Complete Response (pCR) Rate in Participants With PD-L1 Positive Tumors (CPS≥10)
Percentage of ParticipantsPooled Carboplatin+Paclitaxel+Pembrolizumab+Olaparib, and Carboplatin+Paclitaxel+PembrolizumabCarboplatin + Paclitaxel
Pathological Complete Response (pCR) Rate in Participants With PD-L1 Positive Tumors (CPS≥10)9.8 (5.8 to 15.2)4.5 (1.2 to 11.1)
Statistical analysis
  • Pooled Carboplatin+Paclitaxel+Pembrolizumab+Olaparib, and Carboplatin+Paclitaxel+Pembrolizumab vs Carboplatin + Paclitaxel · t-test, 1 sided · p = 0.0644 (One-sided p-value for testing. H0: difference in % = 0 versus H1: difference in % \> 0.) · Difference in percentage: 5.4 · 95% CI -1.9 to 11.5Based on Miettinen \& Nurminen method stratified by bevacizumab use (Yes vs No)
SecondaryPathological Complete Response (pCR) Rate in All Participants

pCR is defined as the disappearance of all known disease noted prior to surgery; all surgical specimens collected during the interval debulking surgery are microscopically negative for malignancy. The percentage of participants who experience pCR was determined based on Miettinen \& Nurminen method stratified by Bevacizumab use (yes versus no) and PD-L1 status (CPS \<10 versus CPS\>=10).

Time frame:
Up to approximately 26 months
Reported as:
Number · Percentage of Participants
Pathological Complete Response (pCR) Rate in All Participants
Percentage of ParticipantsPooled Carboplatin+Paclitaxel+Pembrolizumab+Olaparib, and Carboplatin+Paclitaxel+PembrolizumabCarboplatin + Paclitaxel
Pathological Complete Response (pCR) Rate in All Participants5.9 (3.6 to 9.0)2.3 (0.6 to 5.9)
Statistical analysis
  • Pooled Carboplatin+Paclitaxel+Pembrolizumab+Olaparib, and Carboplatin+Paclitaxel+Pembrolizumab vs Carboplatin + Paclitaxel · t-test, 1 sided · p = 0.0318 (One-sided p-value for testing. H0: difference in % = 0 versus H1: difference in % \> 0.) · Difference in percentage: 3.7 · 95% CI -0.3 to 7.3Based on Miettinen \& Nurminen method stratified by bevacizumab use (Yes vs No) and PD-L1 CPS (\<10 vs ≥10)
SecondaryNumber of Participants Who Experience an Adverse Event (AE)

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.

Time frame:
Up to approximately 73 months (anticipated)

Results for this outcome have not been posted.

SecondaryNumber of Participants Who Discontinue Study Treatment Due to an AE

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

Time frame:
Up to approximately 6 years (anticipated)

Results for this outcome have not been posted.

Adverse events

Collected over Up to approximately 67 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Carboplatin + Paclitaxel + Pembrolizumab + Olaparib237/455 (52.1%)205/452 (45.4%)445/452 (98.5%)
Carboplatin + Paclitaxel + Pembrolizumab243/458 (53.1%)179/456 (39.3%)442/456 (96.9%)
Carboplatin + Paclitaxel229/454 (50.4%)122/454 (26.9%)445/454 (98%)
Most frequent serious events
Showing 10 of 339
Most frequent serious events
EventCarboplatin + Paclitaxel + Pembrolizumab + OlaparibCarboplatin + Paclitaxel + PembrolizumabCarboplatin + Paclitaxel
Febrile neutropeniaBlood and lymphatic system disorders19/45216/4569/454
PyrexiaGeneral disorders15/4527/4564/454
Urinary tract infectionInfections and infestations14/4527/4569/454
COVID-19Infections and infestations9/4522/4563/454
Intestinal obstructionGastrointestinal disorders8/4529/4566/454
PneumoniaInfections and infestations7/4528/4561/454
Small intestinal obstructionGastrointestinal disorders7/4527/4567/454
AnaemiaBlood and lymphatic system disorders6/4525/4564/454
IleusGastrointestinal disorders6/4526/4564/454
COVID-19 pneumoniaInfections and infestations6/4524/4562/454
Most frequent other events
Showing 10 of 64
Most frequent other events
EventCarboplatin + Paclitaxel + Pembrolizumab + OlaparibCarboplatin + Paclitaxel + PembrolizumabCarboplatin + Paclitaxel
AnaemiaBlood and lymphatic system disorders270/452212/456205/454
NauseaGastrointestinal disorders227/452187/456150/454
NeutropeniaBlood and lymphatic system disorders170/452138/456147/454
ArthralgiaMusculoskeletal and connective tissue disorders136/452142/456139/454
DiarrhoeaGastrointestinal disorders121/452138/45694/454
AlopeciaSkin and subcutaneous tissue disorders123/452114/456131/454
ConstipationGastrointestinal disorders121/452122/456104/454
FatigueGeneral disorders120/452115/45685/454
AstheniaGeneral disorders116/45297/45670/454
VomitingGastrointestinal disorders114/45281/45670/454

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Carboplatin + Paclitaxel + Pembrolizumab + OlaparibCarboplatin + Paclitaxel + PembrolizumabCarboplatin + PaclitaxelTotal
Mean60.4 ± 10.659.8 ± 11.059.3 ± 11.659.8 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Carboplatin + Paclitaxel + Pembrolizumab + OlaparibCarboplatin + Paclitaxel + PembrolizumabCarboplatin + PaclitaxelTotal
Female4554584541367
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Carboplatin + Paclitaxel + Pembrolizumab + OlaparibCarboplatin + Paclitaxel + PembrolizumabCarboplatin + PaclitaxelTotal
Hispanic or Latino454145131
Not Hispanic or Latino4104154071232
Unknown or Not Reported0224
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Carboplatin + Paclitaxel + Pembrolizumab + OlaparibCarboplatin + Paclitaxel + PembrolizumabCarboplatin + PaclitaxelTotal
American Indian or Alaska Native1405
Asian777383233
Native Hawaiian or Other Pacific Islander0000
Black or African American74415
White3603673571084
More than one race108927
Unknown or Not Reported0213
08

Study locations

227 sites
  • University of Alabama at Birmingham (UAB) ( Site 0036)
    Birmingham, Alabama 35233, United States
  • University of Arizona Cancer Center ( Site 0074)
    Tucson, Arizona 85719, United States
  • Disney Family Cancer Center ( Site 0042)
    Burbank, California 91505, United States
  • Kaiser Permanente Oncology Clinical Trial -Oakland ( Site 0077)
    Oakland, California 94611, United States
  • Kaiser Permanente Oncology Clinical Trials-Roseville ( Site 0084)
    Roseville, California 95661, United States
  • Kaiser Permanente Oncology Clinical Trials-Sacramento ( Site 0083)
    Sacramento, California 95814, United States
  • Kaiser Permanente Oncology Clinical Trial - San Francisco ( Site 0078)
    San Francisco, California 94115, United States
  • Kaiser Permanente Oncology Clinical Trial - Santa Clara ( Site 0079)
    Santa Clara, California 95051, United States
  • Kaiser Permanente N. CA Regional Oncology Clinical Trials ( Site 0008)
    Vallejo, California 94589, United States
  • Kaiser Permanente Oncology Clinical Trial - Walnut Creek ( Site 0080)
    Walnut Creek, California 94596, United States
  • Smilow Cancer Center at Yale-New Haven ( Site 0057)
    New Haven, Connecticut 06511, United States
  • Sarasota Memorial Hospital ( Site 0023)
    Sarasota, Florida 34239, United States
  • Emory School of Medicine ( Site 0053)
    Atlanta, Georgia 30322, United States
  • Northeast Georgia Medical Center ( Site 0029)
    Gainesville, Georgia 30501, United States
  • Memorial Health University Medical Center ( Site 0011)
    Savannah, Georgia 31404, United States
  • Rush University Medical Center ( Site 0019)
    Chicago, Illinois 60612, United States
  • University of Chicago ( Site 0049)
    Chicago, Illinois 60637, United States
  • Dr. Sudarshan K. Sharma, LTD ( Site 0061)
    Hinsdale, Illinois 60521, United States
  • Saint Vincent Hospital and Health Center ( Site 0012)
    Indianapolis, Indiana 46260, United States
  • University of Iowa Hospital and Clinics ( Site 0005)
    Iowa City, Iowa 52242, United States
  • University of Kentucky ( Site 0045)
    Lexington, Kentucky 40536, United States
  • Weinberg Cancer Institute at Franklin Square ( Site 0035)
    Baltimore, Maryland 21237, United States
  • Saint Dominic - Jackson Memorial Hospital ( Site 0072)
    Jackson, Mississippi 39216, United States
  • Washington University - School of Medicine ( Site 0062)
    St Louis, Missouri 63110, United States
  • Nebraska Methodist Hospital ( Site 0063)
    Omaha, Nebraska 68114, United States
  • Dartmouth Hitchcock Medical Center ( Site 0024)
    Lebanon, New Hampshire 03756, United States
  • MD Anderson Cancer Center at Cooper ( Site 0067)
    Camden, New Jersey 08103, United States
  • Holy Name Medical Center ( Site 0037)
    Teaneck, New Jersey 07666, United States
  • Northwell Health- Monter Cancer Center ( Site 0075)
    Lake Success, New York 11042, United States
  • Sanford Roger Maris Cancer Center ( Site 0082)
    Fargo, North Dakota 58122, United States
  • Miami Valley Hospital [Dayton, OH] ( Site 0073)
    Centerville, Ohio 45459, United States
  • Oncology/Hematology Care Clinical Trials, LLC ( Site 8001)
    Cincinnati, Ohio 45242, United States
  • The Bing Cancer Center ( Site 0044)
    Columbus, Ohio 43214, United States
  • OSU Wexner Medical Center ( Site 0076)
    Hilliard, Ohio 43026, United States
  • Women and Infants Hospital [Providence, RI] ( Site 0039)
    Providence, Rhode Island 02905, United States
  • Sanford Gynecology Oncology ( Site 0004)
    Sioux Falls, South Dakota 57104, United States
  • Texas Oncology, P.A. - Bedford ( Site 8005)
    Bedford, Texas 76022, United States
  • Texas Oncology-Dallas Presbyterian Hospital ( Site 8004)
    Dallas, Texas 75231, United States
  • Parkland Hospital ( Site 0081)
    Dallas, Texas 75235, United States
  • UT Southwestern Medical Center ( Site 0046)
    Dallas, Texas 75390, United States
  • Texas Oncology, P.A. Texas Oncology-Tyler ( Site 8006)
    Tyler, Texas 75702, United States
  • Virginia Cancer Specialists, PC ( Site 8003)
    Gainesville, Virginia 20155, United States
  • MEDICAL COLLEGE OF WISCONSIN ( Site 0064)
    Milwaukee, Wisconsin 53226, United States
  • St George Hospital ( Site 2207)
    Kogarah, New South Wales 2217, Australia
  • Cairns and Hinterland Hospital and Health Service ( Site 2201)
    Cairns, Queensland 4870, Australia
  • Ballarat Health Services ( Site 2202)
    Ballarat, Victoria 3350, Australia
  • Monash Health ( Site 2204)
    Clayton, Victoria 3168, Australia
  • Sunshine Hospital. ( Site 2205)
    St Albans, Victoria 3021, Australia
  • Imelda Ziekenhuis Bonheiden ( Site 0301)
    Bonheiden, Antwerpen 1932, Belgium
  • UZ Leuven Campus Gasthuisberg ( Site 0306)
    Leuven, Antwerpen 3000, Belgium
  • Cliniques Universitaires Saint-Luc ( Site 0312)
    Brussels, Bruxelles-Capitale, Region de 1200, Belgium
  • Grand Hopital de Charleroi ( Site 0302)
    Charleroi, Hainaut 6000, Belgium
  • CHU de Liege ( Site 0310)
    Liège, Liege 4000, Belgium
  • Jessa Ziekenhuis ( Site 0309)
    Hasselt, Limburg 3500, Belgium
  • Centre Hospitalier de l'Ardenne ( Site 0303)
    Libramont, Luxembourg 6800, Belgium
  • AZ Maria Middelares Gent ( Site 0300)
    Ghent, Oost-Vlaanderen 9000, Belgium
  • UZ Gent ( Site 0307)
    Ghent, Oost-Vlaanderen 9000, Belgium
  • Instituto do Cancer do Ceara ( Site 2707)
    Fortaleza, Ceará 60430-230, Brazil
  • Hospital Araujo Jorge Associacao de Combate ao Cancer de Goias ( Site 2708)
    Goiânia, Goiás 74605-070, Brazil
  • Hospital Erasto Gaertner ( Site 2716)
    Curitiba, Paraná 82520-060, Brazil
  • Hospital de Caridade de Ijui ( Site 2712)
    Ijuí, Rio Grande do Sul 98700-000, Brazil
  • Hospital Bruno Born ( Site 2704)
    Lajeado, Rio Grande do Sul 95900-000, Brazil
  • Hospital Nossa Senhora Da Conceicao ( Site 2703)
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
  • Instituto Nacional de Cancer Hospital do Cancer II ( Site 2700)
    Rio de Janeiro, 20220-410, Brazil
  • Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 2714)
    São Paulo, 01246-000, Brazil
  • Clinica de Pesquisas e Ctro de Estudos Onc. Ginecol. e Mamaria Ltda ( Site 2706)
    São Paulo, 01317-000, Brazil
  • Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 2710)
    São Paulo, 01321-001, Brazil
  • Tom Baker Cancer Centre ( Site 0200)
    Calgary, Alberta T2N 4N2, Canada
  • Kingston Health Sciences Centre ( Site 0207)
    Kingston, Ontario K7L 2V7, Canada
  • The Credit Valley Hospital ( Site 0206)
    Mississauga, Ontario L5M 2N1, Canada
  • Princess Margaret Hospital.. ( Site 0202)
    Toronto, Ontario M5G 2M9, Canada
  • CIUSSS du Saguenay-Lac-St-Jean ( Site 0218)
    Chicoutimi, Quebec G7H 5H6, Canada
  • CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0219)
    Montreal, Quebec H1T 2M4, Canada
  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0208)
    Montreal, Quebec H2X 0A9, Canada
  • Royal Victoria Hospital McGill University Health Centre ( Site 0211)
    Montreal, Quebec H4A 3J1, Canada
  • Centro Investigación del Cáncer James Lind ( Site 2810)
    Temuco, Araucania 4780000, Chile
  • Centro de Investigacion y desarrollo Oncologico SpA - CIDO SpA ( Site 2808)
    Temuco, Araucania 4810218, Chile
  • Fundacion Arturo Lopez Perez FALP ( Site 2800)
    Santiago, Region M. de Santiago 7500922, Chile
  • Sociedad Oncovida S.A. ( Site 2807)
    Santiago, Region M. de Santiago 7510032, Chile
  • Iram Cancer Research ( Site 2809)
    Santiago, Region M. de Santiago 7630370, Chile
  • Pontificia Universidad Catolica de Chile ( Site 2805)
    Santiago, Region M. de Santiago 8330032, Chile
  • Oncocentro ( Site 2801)
    Viña del Mar, Valparaiso 2520598, Chile
  • Centro Oncologico Antofagasta ( Site 2804)
    Antofagasta, 1240000, Chile
  • Biomelab S A S ( Site 2900)
    Barranquilla, Atlántico 080002, Colombia
  • Instituto Nacional de Cancerologia E.S.E ( Site 2910)
    Bogotá, Bogota D.C. 110321, Colombia
  • Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 2912)
    Bogotá, Bogota D.C. 111321, Colombia
  • Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 2913)
    Valledupar, Cesar Department 200001, Colombia
  • Oncomedica S.A. ( Site 2911)
    Montería, Departamento de Córdoba 230002, Colombia
  • Centro Medico Imbanaco de Cali S.A ( Site 2909)
    Cali, Valle del Cauca Department 760042, Colombia
  • Hemato Oncologos S.A. ( Site 2906)
    Cali, Valle del Cauca Department 760042, Colombia
  • Fakultni nemocnice Brno ( Site 0404)
    Brno, Brno-mesto 602 00, Czechia
  • Fakultni nemocnice Ostrava ( Site 0403)
    Ostrava-Poruba, Moravian-Silesian Region 708 52, Czechia
  • Vseobecna fakultni nemocnice v Praze ( Site 0400)
    Prague, Praha, Hlavni Mesto 120 00, Czechia
  • Nemocnice Na Bulovce ( Site 0401)
    Prague, Praha, Hlavni Mesto 180 81, Czechia
  • Fakultni nemocnice Olomouc ( Site 0402)
    Olomouc, 779 00, Czechia
  • Hopital Prive Jean Mermoz ( Site 0607)
    Lyon, Auvergne 69008, France
  • Centre Paul Strauss ( Site 0615)
    Strasbourg, Bas-Rhin 67065, France
  • Hopital de la Timone ( Site 0617)
    Marseille, Bouches-du-Rhone 13005, France
  • CHU de Brest -Site Hopital Morvan ( Site 0616)
    Brest, Brittany Region 29200, France
  • Institut de Cancerologie du Gard - CHU Caremeau ( Site 0610)
    Nîmes, Gard 30029, France

Showing the first 100 of 227 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Aug 2024, 68 months.

Results were first posted in Sep 2025, 1 year after primary completion.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's 68 months is above that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2018
First posted
Nov 14, 2018
StartActual
Dec 18, 2018
Primary completionActual
Aug 26, 2024
CompletionActual
Apr 14, 2026
Results first posted
Sep 12, 2025
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03740165
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT), Gynecologic Oncology Group
Responsible party
Sponsor
First posted
Nov 14, 2018
Start date
Dec 18, 2018
Primary completion
Aug 26, 2024
Completion
Apr 14, 2026
Results posted
Sep 12, 2025
Last update
Aug 19, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pembrolizumab · Olaparib

Start the discussion